CD47 and hematologic disorder: Among them, clinical trials with monoclonal anti-human CD47 antibody (Hu5F9-G4, CC-90002, SRF231, IBI188) or recombinant SIRPα-Fc protein (TTI-621, ALX148, TTI-622) were applied as a monotherapy or combination with immune checkpoint inhibitors in patients with solid tumors or hematologic malignancies in clinical trial Phase I (NCT02216409, NCT02953782, NCT03558139, NCT02367196, NCT02663518, NCT03013218, NCT03512340, NCT03530683, NCT03717103.